JP2012529433A5 - - Google Patents

Download PDF

Info

Publication number
JP2012529433A5
JP2012529433A5 JP2012514221A JP2012514221A JP2012529433A5 JP 2012529433 A5 JP2012529433 A5 JP 2012529433A5 JP 2012514221 A JP2012514221 A JP 2012514221A JP 2012514221 A JP2012514221 A JP 2012514221A JP 2012529433 A5 JP2012529433 A5 JP 2012529433A5
Authority
JP
Japan
Prior art keywords
xaa
alkyl
aryl
cyclic peptide
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012514221A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012529433A (ja
JP5805632B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/037589 external-priority patent/WO2010144344A2/en
Publication of JP2012529433A publication Critical patent/JP2012529433A/ja
Publication of JP2012529433A5 publication Critical patent/JP2012529433A5/ja
Application granted granted Critical
Publication of JP5805632B2 publication Critical patent/JP5805632B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012514221A 2009-06-08 2010-06-07 メラノコルチン受容体に特異的なペプチド Active JP5805632B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18492909P 2009-06-08 2009-06-08
US61/184,929 2009-06-08
PCT/US2010/037589 WO2010144344A2 (en) 2009-06-08 2010-06-07 Melanocortin receptor-specific peptides

Publications (3)

Publication Number Publication Date
JP2012529433A JP2012529433A (ja) 2012-11-22
JP2012529433A5 true JP2012529433A5 (enExample) 2013-07-25
JP5805632B2 JP5805632B2 (ja) 2015-11-04

Family

ID=43309425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012514221A Active JP5805632B2 (ja) 2009-06-08 2010-06-07 メラノコルチン受容体に特異的なペプチド

Country Status (14)

Country Link
US (4) US8846601B2 (enExample)
EP (1) EP2440227B1 (enExample)
JP (1) JP5805632B2 (enExample)
KR (1) KR101726893B1 (enExample)
CN (2) CN102458436B (enExample)
AU (1) AU2010259008C1 (enExample)
BR (1) BRPI1009644B1 (enExample)
CA (1) CA2761607C (enExample)
EA (1) EA020959B1 (enExample)
IL (1) IL216843A (enExample)
MX (1) MX2011013117A (enExample)
NZ (1) NZ596617A (enExample)
WO (1) WO2010144344A2 (enExample)
ZA (1) ZA201200112B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
CA2761607C (en) 2009-06-08 2018-09-04 Yi-Qun Shi Melanocortin receptor-specific peptides
JP5999702B2 (ja) * 2009-11-23 2016-09-28 パラティン テクノロジーズ, インコーポレイテッドPalatin Technologies, Inc. メラノコルチン−1受容体特異的環状ペプチド
WO2012100342A1 (en) 2011-01-27 2012-08-02 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
LT3539551T (lt) 2011-12-29 2022-01-10 Rhythm Pharmaceuticals, Inc. Su melanokortino-4 receptoriumi susijusių sutrikimų gydymo būdas heterozigotiniuose nešiotojuose
EP2809660B1 (en) * 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
EP2970388B1 (en) * 2013-03-15 2018-07-25 Rhythm Pharmaceuticals, Inc. Peptide compositions
CN115957297A (zh) 2013-03-15 2023-04-14 节奏制药公司 药物组合物
WO2015162287A1 (en) * 2014-04-25 2015-10-29 Phi Pharma Sa Keratan sulfate specific transporter molecules
CN104436159A (zh) * 2014-12-09 2015-03-25 天津医科大学眼科医院 一种新型滴眼液对治疗干眼的用途
WO2016168388A2 (en) * 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
PL3356386T3 (pl) * 2015-09-30 2024-08-05 Rhythm Pharmaceuticals, Inc. Sposób leczenia zaburzeń związanych ze szlakiem receptora melanokortyny 4
US11174298B2 (en) * 2016-11-09 2021-11-16 James P. Tam Preparation and use of ginsentides and ginsentide-like peptides
CA3095036A1 (en) * 2018-03-23 2019-09-26 Palatin Technologies, Inc. Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery
US20210169969A1 (en) 2018-04-06 2021-06-10 Leonardus H.T. Van Der Ploeg Compositions for treating kidney disease
CN115515617A (zh) * 2020-02-03 2022-12-23 帕拉丁科技公司 二胺连接的受体特异性环状肽
JP7735282B2 (ja) * 2020-02-03 2025-09-08 パラティン テクノロジーズ, インコーポレイテッド 逆アミド結合を持つメラノコルチン受容体に特異的な環状ペプチド
CN114890958B (zh) * 2022-02-23 2023-10-20 四川警察学院 双光子染料化合物、其制备方法及其应用
CN115521356B (zh) * 2022-08-17 2024-04-02 桂林医学院 一种具有美白功效的多肽及其应用
CN119529031B (zh) * 2024-11-27 2025-12-05 润辉生物技术(威海)有限公司 一种环肽衍生物及其制备方法与应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
ATE164080T1 (de) 1990-05-10 1998-04-15 Bechgaard Int Res Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole
US6100048A (en) 1992-04-10 2000-08-08 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US6054556A (en) 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
US7396814B2 (en) 1995-06-07 2008-07-08 Palatin Technologies, Inc. Metallopeptide compositions for treatment of sexual dysfunction
JP2001506996A (ja) 1996-12-17 2001-05-29 クアドラント ホールディングス ケンブリッジ リミテッド メラノコルチン受容体3、4又は5の特異結合のためのメラノコルチン誘導体
JP4642946B2 (ja) 1996-12-20 2011-03-02 アルザ コーポレイション ゲル組成物および方法
US5908825A (en) 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same
WO1999021571A1 (en) 1997-10-27 1999-05-06 Trega Biosciences, Inc. Melanocortin receptor ligands and methods of using same
US6193991B1 (en) 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
GB9808229D0 (en) 1998-04-17 1998-06-17 Quadrant Holdings Cambridge Melanocortin receptor ligands
SE9801571D0 (sv) 1998-05-05 1998-05-05 Wapharm Ab Melanokortin-1-receptorselektiva föreningar
GB9816234D0 (en) 1998-07-24 1998-09-23 William Harvey Research Limite Compounds for use in the treatment of inflammation
GB9827500D0 (en) 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
US6887846B2 (en) 1999-03-24 2005-05-03 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
CA2368431C (en) 1999-03-29 2006-01-24 The Procter & Gamble Company Melanocortin receptor ligands
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US6699873B1 (en) 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
WO2001030808A1 (en) 1999-10-27 2001-05-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor-ligand binding
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
AU2001229491A1 (en) 2000-01-18 2001-07-31 Merck And Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
US6600015B2 (en) 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
AU2001261363A1 (en) 2000-05-09 2001-11-20 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
GB0012370D0 (en) 2000-05-22 2000-07-12 Quadrant Holdings Cambridge Peptoids
SI1315750T1 (sl) 2000-08-30 2007-06-30 Hoffmann La Roche Cikliäśni peptidi kot agonisti za receptorje melanokortina-4
EP1409540A2 (en) 2000-09-27 2004-04-21 The Procter & Gamble Company Melanocortin receptor ligands
US7345144B2 (en) 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
EP1441750A4 (en) * 2001-07-11 2006-10-18 Palatin Technologies Inc LINEAR AND CYCLIC PEPTIDES SPECIFIC TO THE MELANOCORTIN RECEPTOR
US7342089B2 (en) 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
US6960646B2 (en) 2001-07-12 2005-11-01 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptors agonists
FR2835528B1 (fr) 2002-02-01 2004-03-12 Inst Europ Biolog Cellulaire Nouveaux derives peptidiques, leur preparation et leur application therapeutique et cosmetique
US7034004B2 (en) 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
WO2004005324A2 (en) 2002-07-09 2004-01-15 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
US7135548B2 (en) 2002-11-14 2006-11-14 Zengen, Inc. Modified α-MSH peptides and derivatives thereof
WO2004046166A2 (en) 2002-11-14 2004-06-03 Zengen, Inc. Modified alpha-msh peptides and derivatives thereof
US7183255B2 (en) 2003-02-26 2007-02-27 Intradialytic Pharmaceuticals Method for stabilizing blood pressure in hemodialysis subjects
KR20060026011A (ko) 2003-05-09 2006-03-22 노보 노르디스크 에이/에스 비만 치료용 펩티드
BRPI0409976A (pt) 2003-05-09 2006-05-09 Novo Nordisk As composto, métodos para retardar a progressão de igt diabetes do tipo 2, para retardar a progressão de diabetes do tipo 2 para diabetes que requer insulina, para tratar obesidade ou prevenir excesso de peso para regular o apetite para induzir saciedade, para prevenir ganho de peso após se ter tido sucesso em perder peso, para aumentar dispêndio de energia, para tratar uma doença ou estado e para tratar bulimia, composição farmacêutica, e, uso de um composto
EP1644023A2 (en) * 2003-06-19 2006-04-12 Eli Lilly And Company Melanocortin recptor 4(mc4) agonists and their uses
EP1644022A1 (en) 2003-06-19 2006-04-12 Eli Lilly And Company Uses of melanocortin-3 receptor (mc3r) agonist peptides
CN1809372A (zh) * 2003-06-19 2006-07-26 伊莱利利公司 黑皮质素受体4(mc4)激动剂及其用途
US7084111B2 (en) 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
EP1658285B1 (en) 2003-08-20 2007-05-02 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
EP1670815A2 (en) * 2003-09-30 2006-06-21 Novo Nordisk A/S Melanocortin receptor agonists
DK1689349T3 (da) 2003-11-24 2013-12-02 Clinuvel Pharmaceuticals Ltd Fremgangsmåde til induktion af melanogenese i mennesker med variante MC1R-alleler
WO2005060985A1 (en) 2003-12-10 2005-07-07 Merck & Co., Inc. Inhibition of voluntary ethanol consumption with selective melanocortin 4-receptor agonists
JP2007530674A (ja) 2004-03-29 2007-11-01 イーライ リリー アンド カンパニー 連続注入によって投与されるメラノコルチン−4受容体(mc4r)アゴニストペプチドの使用
NZ582130A (en) 2004-08-04 2011-11-25 Clinuvel Pharmaceuticals Ltd Methods of inducing melanogenesis in a subject
RS51789B (sr) 2004-10-25 2011-12-31 Centocor Ortho Biotech Inc. Mimetička tela koja vezuju receptore melanokortina, smese, postupci i upotrebe
US20110098213A1 (en) 2004-11-04 2011-04-28 Novo Nordisk A/S Novel peptides for use in the treatment of obesity
CN101052649A (zh) 2004-11-04 2007-10-10 诺和诺德公司 用于治疗肥胖的肽类
JP2008519006A (ja) 2004-11-04 2008-06-05 ノボ ノルディスク アクティーゼルスカブ 肥満症の治療に使用するためのペプチド
CN101052650A (zh) 2004-11-04 2007-10-10 诺和诺德公司 用于治疗肥胖的新颖的肽类
WO2006097526A1 (en) 2005-03-17 2006-09-21 Novo Nordisk A/S Compounds for use in the treatment of obesity
JP2009500426A (ja) 2005-07-08 2009-01-08 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス メラノコルチン受容体のリガンド
NZ565217A (en) 2005-07-08 2010-03-26 Ipsen Pharma Sas Melanocortin receptor ligands
CN101222942A (zh) 2005-07-18 2008-07-16 诺沃-诺迪斯克有限公司 用于治疗肥胖的肽
EP1957096A4 (en) 2005-08-29 2012-03-21 Palatin Technologies Inc CYCLIC PEPTIDE INSULATION BY SPRAY DRYING
US8114844B2 (en) * 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
DK2865422T3 (da) 2006-08-31 2017-11-20 Clinuvel Pharmaceuticals Ltd Alpha-msh-derivater til behandling af fotodermatoser
CN101177450A (zh) * 2006-11-09 2008-05-14 武汉聚奇医药科技有限公司 引发男性阴茎勃起和提高女性性欲的短肽
WO2008087186A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
US20100056433A1 (en) 2007-01-18 2010-03-04 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
US20100016238A1 (en) 2007-01-18 2010-01-21 Novo Nordisk A/S Peptides for Use in the Treatment of Obesity
US20100022446A1 (en) 2007-01-18 2010-01-28 Novo Nordisk A/S Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
CN101302246B (zh) * 2007-05-09 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 黑色素皮质激素受体七肽类激动剂及其制备方法和用途
EP2167112A4 (en) 2007-06-15 2012-01-25 Ipsen Pharma Sas CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS
BRPI0819188B1 (pt) 2007-11-05 2021-06-22 Ipsen Pharma S.A.S. Uso de melanocortinas para a preparação de um medicamento para tratar resistência à insulina
KR101687037B1 (ko) * 2008-06-09 2016-12-15 팔라틴 테크놀로지스 인코포레이티드 성기능 장애 치료용 멜라노코르틴 수용체-특이적 펩티드
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
CA2761607C (en) * 2009-06-08 2018-09-04 Yi-Qun Shi Melanocortin receptor-specific peptides

Similar Documents

Publication Publication Date Title
JP2012529433A5 (enExample)
JP2013511553A5 (enExample)
JP2013511554A5 (enExample)
JP2016523241A5 (enExample)
RU2014137107A (ru) Пептидомиметические макроциклы
CN102711802B (zh) 肽glp‑2激动剂
JP2020502051A5 (enExample)
EP0804463A1 (de) Neurokinin (tachykinin)-antagonisten
JP2013533864A5 (enExample)
MY161450A (en) Double-acylated glp-1 derivatives
JP2009527499A5 (enExample)
KR20140014081A (ko) 아밀로이드 피브릴 형성과 관련된 증상 치료용 디펩티드 유사체
RU2010123466A (ru) Пептидное производное - миметик эритропоэтина и его фармацевтические соли, их получение и применение
US20230183291A1 (en) Anti-infective bicyclic peptide ligands
JP2019501214A5 (enExample)
RU2006144279A (ru) Пептидные соединения
RS54722B1 (sr) Agonisti v1a receptora
JP2023511184A5 (enExample)
CN105658670A (zh) 肽-低聚尿素嵌合化合物及其使用方法
JP2018531284A6 (ja) 環状ポリペプチド、それらを得る方法、及びその治療的使用
JP2018531284A (ja) 環状ポリペプチド、それらを得る方法、及びその治療的使用
AU744425B2 (en) 20(s) camptothecin glycoconjugates
CA3206846A1 (en) Anti-infective bicyclic peptide ligands
RU2007118385A (ru) Контрастные агенты для направлений доставки во внеклеточный матрикс
JP2020189806A (ja) 複合体